|
Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes
|
Jul 2017
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure
|
Mar 2017
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Heterogeneity in the Myelodysplastic Syndromes: Moving Toward a Better Understanding
|
Jan 2013
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Paroxysmal Nocturnal Hemoglobinuria (PNH) is not a Cause for Anemia in Patients with Myelofibrosis
|
Dec 2013
|
Leuk Lymphoma
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Methylation of Promoters of microRNAs and their Host Genes in Myelodysplastic Syndromes.
|
Apr 2013
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Shelf-life Extension of Azacitidine: Waste and Cost Reduction in the Treatment of Myelodysplastic Syndromes
|
May 2014
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
The Revised International Prognostic Scoring System (IPSS-R) is not Predictive of Survival in Patients with Secondary Myelodysplastic Syndromes
|
Apr 2015
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care
|
Jun 2018
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
The Myelodysplastic Syndromes (MDS): A personal recollection of four decades of classification and prognostic scoring systems.
|
Apr 2013
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications
|
Dec 2016
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
